Stroke Prevention in Atrial Fibrillation III "SPAF III"


Phase N/A Results


The trial was halted when the rate of ischemic stroke and systemic embolism in patients given combination therapy was significantly higher than in those given adjusted-dose warfarin (7.9% vs. 1.9% per year) at an interim analysis. The annual rates of disabling stroke and of primary event or vascular death were also higher with combination therapy.